DiaKine Therapeutics, Inc.'s Lead Compound in Phase 2 Clinical Trial

October 14, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--DiaKine Therapeutics, developers of drugs designed to cause diabetes to go into remission, announced today that a Phase 2 Clinical Trial with the Company’s lead drug candidate, Lisofylline (LSF), is underway.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase II